Hormone therapy in older women with breast cancer was associated with a reduced risk of subsequent dementia, a retrospective study of Medicare patients suggested. Breast cancer patients who received ...
Hormone modulating therapy (HMT) used for the treatment of breast cancer was associated with a 7% lower risk of developing Alzheimer's disease and related dementias later in life, according to a new ...
Selective estrogen receptor modulators (SERMs) bind to hormone receptors, preventing estrogen from binding. Examples of SERMs approved by the FDA are tamoxifen (Nolvadex), raloxifene (Evista), and ...
Hormone modulating therapy (HMT) used for the treatment of breast cancer was associated with a 7% lower risk of developing Alzheimer's disease and related dementias later in life, according to a new ...
(A) The AlphaFold protein structure of GPER from the public database (https://alphafold.com/entry/Q99527). (B) E2, the GPER-specific agonist G1, SERMs, and SERDs ...
CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...
If you have metastatic breast cancer that’s hormone receptor-positive (HR+) and HER2-negative, your treatment plan looks very different from how it might have decades ago. Instead of relying on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results